Talk:Subcutaneous injection
Discussion page·3 threads·no archives
This is the discussion page for the article Subcutaneous injection. It is for improving the article: sources, wording, structure, scope and titles. It is not a general discussion forum about the subject, and it is not a place to ask for advice — see Project:Medical disclaimer.
Extrapolating insulin site dataResolved
The site-difference table comes from insulin work. The article says so and explains why the extrapolation matters less for long-acting peptides, which is the right handling. — SubQ_Solveig (talk) 09:35, 22 February 2026 (UTC)
Absorption being non-rate-limiting is the reason, and stating it gives the reader a way to judge other extrapolations for themselves. ✓ Done — HalfLifeHavel (talk) 13:10, 22 February 2026 (UTC)
Needle length and intramuscular deliveryDone
Short needles are now standard precisely because of the intramuscular risk. Good that the article gives the mechanism rather than only the recommendation. — NurseNoteNessa (talk) 10:50, 14 May 2026 (UTC)
And notes that the consequence is smaller for long-acting peptides than for insulin, which keeps it proportionate. ✓ Done — SyringeSybille (talk) 14:25, 14 May 2026 (UTC)
Usage note on the word subQ
The infobox lists "subQ" as an abbreviation. It is informal. Keep or drop? — ManualOfStyleMo (talk) 11:15, 30 June 2026 (UTC)
Keep. It is what readers will have seen, and listing it is not endorsing it. Same reasoning as "twincretin" at Dual incretin agonist. — GlossaryGleb (talk) 14:40, 30 June 2026 (UTC)